A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF‐antagonists

Abstract

Background Adult pityriasis rubra pilaris (PRP) type 1 is a rare chronic papulosquamous disorder with clinical

Analysis of CARD14 Polymorphisms in Pityriasis Rubra Pilaris: Activation of NF-κB

“…Pityriasis rubra pilaris (PRP) is a rare inflammatory papulo-squamous disorder manifesting with palmoplantar keratoderma and follicular hyperkeratotic papules which tend to coalesce into large, scaly, erythematous plaques often progressing to exfoliative erythroderma (Klein et al , 2010; Petrof et al , 2013). PRP is often misdiagnosed as psoriasis, a more common papulo-squamous inflammatory disorder.…”

Alitretinoin (9-cis Retinoic Acid) is Effective Against Pityriasis Rubra Pilaris: A Retrospective Clinical Study

“…In vitro, alitretinoin showed higher affinity to RAR than to RXR and inhibited production of nitric oxide and proinflammatory cytokines such as tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-12p40 (11,12). Accordingly, efficacy of TNF-α inhibitors and the blocking IL-12/IL-23 anti-p40 monoclonal antibody ustekinumab was also shown in PRP case reports (13)(14)(15). Hence, beneficial therapeutic effects of alitretinoin in PRP might possibly be due to suppression of TNF-α and IL-12/IL-23 cytokines.…”

Dermatose érythémato-squameuse à surface râpeuse et paumes orangées

“…Des prises en charge par les inhibiteurs du tumor necrosis factor alpha sont décrites. Ils pourraient avoir un intérêt dans l'avenir [2,[11][12][13][14][15]. …”